MAKING THE CONNECTION
DEEP DIVE SERIES:
Prevention, Early Detection and Aggressive Management of CAD and CKD
An Online Continuing Medical Education Activity
MARCH 25, 2021 | 4:00PM PT
This is a 1.5 hour interactive program
Coronary artery and chronic kidney disease are serious complications of diabetes that often lead to morbidity and mortality, as well as take a toll on the entire family. Making a significant impact involves not only prevention and early detection, but also aggressive management of both heart and kidney disease. In addition to discussing the basics of treating heart and kidney disease, we will do a deep dive into the cardiorenal effects of SGLT2 inhibitors and GLP1RAs to help you help your patients prevent, detect, and manage coronary artery and chronic kidney disease.
This is a 1.5-hour interactive program, please see the full accreditation information here.
WHAT YOU WILL LEARN
In this deep dive, we will focus on the prevention, early detection and aggressive management of CAD and CKD:
• Explain the data related to heart disease as the most common cause of death in type 2 diabetes
• Provide an overview of the results of the cardiovascular outcome trials that have dramatically changed the way we treat type 2 diabetes
• Summarize the ADA treatment guidelines informing healthcare providers about the types of medications to use for type 2 diabetes
• Describe the cardiovascular as well as renal and obesity benefits related to SGLT2s and GLP1RAs improving outcomes for patients
Who Can Benefit Most From This Program:
This course is designed for diabetes healthcare providers including endocrinologists, primary care physicians, nurse practitioners, physician assistants, nurses, certified diabetes educators, pharmacists, registered dieticians, and other healthcare providers wanting to expand their knowledge of diabetes management.
Upon completion of these activities, participants should be able to:
• Identify the different pathophysiologic defects associated with type 2 diabetes and how all the pharmacologic agents (oral and injectable) address these specific abnormalities.
• Discuss the recently published cardiovascular-renal outcome trials on oral (SGLT2 inhibitors) and injectable type 2 medications (GLP1-RAS).
• Evaluate the use of SGLT-2 and GLP-1 RA in patients who have cardiovascular risks factors and are at risk or have a history of atherosclerotic cardiovascular disease (ASCVD).
*Steven V. Edelman, MD
Founder and Director TCOYD, Professor of Medicine, University Of California San Diego, Veterans Affairs Medical Center
James R. Gavin III, MD, PhD
Clinical Professor of Medicine, Emory University
Chief Medical Officer for Healing Our Village, INC in Atlanta, GA
Daniel G. Blanchard, MD, FACC
Professor of Clinical Medicine
Director, University of California, San Diego (UCSD) Cardiology Fellowship Program
UCSD Sulpizio Cardiovascular Center
4:00-5:00 PM (PT): Lecture | 5:00-5:30 PM (PT): Live Q&A
This is a 1.5 hour interactive program
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of California San Diego School of Medicine and Taking Control of Your Diabetes. The University of California San Diego School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
AMA: The University of California San Diego School of Medicine designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses: For the purposes of recertification, the American Nurses Credentialing Center accepts AMA PRA Category 1 credits™ issued by organizations accredited by the ACCME. For the purpose of re-licensure, the California Board of Registered Nursing accepts AMA PRA Category 1 credits™.
Physician Assistants: The AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 credits™ from organizations accredited for ACCME or a recognized state medical society.
Certified Diabetes Care and Education Specialists: The University of California San Diego is accredited by the ACCME, which is on the NCBDE list of approved providers.
Global Education Group designates this continuing education activity for 1.5 contact hour(s) (0.15 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number – 0530-9999-21-015-L01-P)
This is a knowledge based activity.
Attention HCPs from outside of the US: To see if you are eligible to receive CME credits check here.
Cultural and Linguistic Competency
This activity is in compliance with California Assembly Bill 1195 which requires continuing medical education activities with patient care components to include curriculum in the subjects of cultural and linguistic competency. Cultural competency is defined as a set of integrated attitudes, knowledge, and skills that enables health care professionals or organizations to care effectively for patients from diverse cultures, groups, and communities. Linguistic competency is defined as the ability of a physician or surgeon to provide patients who do not speak English or who have limited ability to speak English, direct communication in the patient’s primary language. Cultural and linguistic competency was incorporated into the planning of this activity. Additional resources can be found on the UC San Diego CME website.
This activity is jointly provided by Taking Control Of Your Diabetes and UC San Diego School of Medicine.